Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

In vivo genome editing improves motor function and extends survival in a mouse model of ALS.

Gaj T, Ojala DS, Ekman FK, Byrne LC, Limsirichai P, Schaffer DV.

Sci Adv. 2017 Dec 20;3(12):eaar3952. doi: 10.1126/sciadv.aar3952. eCollection 2017 Dec.

2.

Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas.

Day TP, Byrne LC, Flannery JG, Schaffer DV.

Methods Mol Biol. 2018;1715:239-249. doi: 10.1007/978-1-4939-7522-8_17.

PMID:
29188518
3.

Anti-VEGF AAV2 injections: The fewer the better.

Byrne LC.

Sci Transl Med. 2017 Jun 7;9(393). pii: eaan4921. doi: 10.1126/scitranslmed.aan4921.

PMID:
28592565
4.

What's old is new again: Autologous stem cell transplant for AMD.

Byrne LC.

Sci Transl Med. 2017 Apr 26;9(387). pii: eaan2783. doi: 10.1126/scitranslmed.aan2783.

PMID:
28446683
5.

Massively parallel cis-regulatory analysis in the mammalian central nervous system.

Shen SQ, Myers CA, Hughes AE, Byrne LC, Flannery JG, Corbo JC.

Genome Res. 2016 Feb;26(2):238-55. doi: 10.1101/gr.193789.115. Epub 2015 Nov 17.

6.

Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis.

Aït-Ali N, Fridlich R, Millet-Puel G, Clérin E, Delalande F, Jaillard C, Blond F, Perrocheau L, Reichman S, Byrne LC, Olivier-Bandini A, Bellalou J, Moyse E, Bouillaud F, Nicol X, Dalkara D, van Dorsselaer A, Sahel JA, Léveillard T.

Cell. 2015 May 7;161(4):817-32. doi: 10.1016/j.cell.2015.03.023.

7.

CRALBP supports the mammalian retinal visual cycle and cone vision.

Xue Y, Shen SQ, Jui J, Rupp AC, Byrne LC, Hattar S, Flannery JG, Corbo JC, Kefalov VJ.

J Clin Invest. 2015 Feb;125(2):727-38. doi: 10.1172/JCI79651. Epub 2015 Jan 20.

8.

Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration.

Byrne LC, Dalkara D, Luna G, Fisher SK, Clérin E, Sahel JA, Léveillard T, Flannery JG.

J Clin Invest. 2015 Jan;125(1):105-16. doi: 10.1172/JCI65654. Epub 2014 Nov 21.

9.

The expression pattern of systemically injected AAV9 in the developing mouse retina is determined by age.

Byrne LC, Lin YJ, Lee T, Schaffer DV, Flannery JG.

Mol Ther. 2015 Feb;23(2):290-6. doi: 10.1038/mt.2014.181. Epub 2014 Sep 16.

10.

Retinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h-/- mouse.

Byrne LC, Oztürk BE, Lee T, Fortuny C, Visel M, Dalkara D, Schaffer DV, Flannery JG.

Gene Ther. 2014 Jun;21(6):585-92. doi: 10.1038/gt.2014.31. Epub 2014 Apr 3.

11.

Advances in AAV vector development for gene therapy in the retina.

Day TP, Byrne LC, Schaffer DV, Flannery JG.

Adv Exp Med Biol. 2014;801:687-93. doi: 10.1007/978-1-4614-3209-8_86. Review.

12.

AAV-mediated, optogenetic ablation of Müller Glia leads to structural and functional changes in the mouse retina.

Byrne LC, Khalid F, Lee T, Zin EA, Greenberg KP, Visel M, Schaffer DV, Flannery JG.

PLoS One. 2013 Sep 27;8(9):e76075. doi: 10.1371/journal.pone.0076075. eCollection 2013.

13.

In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous.

Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, Flannery JG, Schaffer DV.

Sci Transl Med. 2013 Jun 12;5(189):189ra76. doi: 10.1126/scitranslmed.3005708.

14.

Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9.

Dalkara D, Byrne LC, Lee T, Hoffmann NV, Schaffer DV, Flannery JG.

Gene Ther. 2012 Feb;19(2):176-81. doi: 10.1038/gt.2011.163. Epub 2011 Oct 20.

PMID:
22011645
15.

Somatic mosaicism in a male with an exon skipping mutation in PDHA1 of the pyruvate dehydrogenase complex results in a milder phenotype.

Okajima K, Warman ML, Byrne LC, Kerr DS.

Mol Genet Metab. 2006 Feb;87(2):162-8. Epub 2006 Jan 18.

PMID:
16412675
16.

Altered NPY and AgRP in membrane type-1 matrix metalloproteinase-deficient mice.

Byrne LC, Zhou Z, Tryggvason K, Hökfelt T, Fetissov SO.

Neuroreport. 2004 Mar 1;15(3):569-74.

PMID:
15094525
17.

Characterization of neuropeptide Y Y2 and Y5 receptor expression in the mouse hypothalamus.

Fetissov SO, Byrne LC, Hassani H, Ernfors P, Hökfelt T.

J Comp Neurol. 2004 Mar 8;470(3):256-65.

PMID:
14755515
18.

Neuropeptide y targets in the hypothalamus: nitric oxide synthesizing neurones express Y1 receptor.

Fetissov SO, Xu ZQ, Byrne LC, Hassani H, Ernfors P, Hökfelt T.

J Neuroendocrinol. 2003 Aug;15(8):754-60.

PMID:
12834436

Supplemental Content

Loading ...
Support Center